Thyme Care Raises $125M Series E, Forms Thyme Companies

Corporate Action
โดย PR Newswire·US·Read original
Summary · why it matters

Thyme Care, a Nashville-based oncology company, announced a Series E financing round of over $125 million, led by Morgan Health with participation from Humana, CVS Health Ventures, and other investors, at a valuation exceeding $2 billion. The company also established Thyme Companies, a new parent entity aimed at building a portfolio of oncology-focused businesses to address challenges such as biosimilar adoption and clinical trial enrollment. Thyme Care, which serves over 10.5 million people across all 50 states and manages more than $7 billion in oncology spend, reports validated cost reductions of 5 to 10 percent and is profitable with positive free cash flow. Co-founder Robin Shah will become executive chairman of Thyme Companies, while Brad Diephuis remains CEO of Thyme Care, with Bobby Green as president and chief medical officer. The first new business under Thyme Companies is expected to launch later this year.

Impact on stocks 2

Aging Population▲ · 2 stocks
Humana Inc
HUM
▲ PositiveCapitalrelevance

Humana participated in Thyme Care's $125M Series E financing round, a direct investment in the oncology company.

Off-coverage companies 2

Thyme CarePrivate▲ Positive
Capitalrelevance

Thyme Care raised over $125M in Series E funding at a valuation exceeding $2 billion, led by Morgan Health with CVS Health Ventures and Humana participating.

Thyme CompaniesPrivate▲ Positive
Capitalrelevance

Thyme Companies was newly established as the parent entity of Thyme Care, formed alongside the $125M Series E raise.

© 2026 MarketDXNews